Non-Glutamatergic Clozapine Augmentation Strategies: A Review and Meta-Analysis

Pharmacopsychiatry

Volumn 47, Issue 7, 2014, Pages 231-238

  Veerman, S R T ^a   Schulte, P F J ^b   Begemann, M J H ^c   De Haan, L ^d  

^a Mental Health Service Organisation North Holland North   (Netherlands)

^b Treatment Centre for Bipolar Disorders   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

augmentation; clozapine; refractory; schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; NEUROLEPTIC AGENT; PLANT MEDICINAL PRODUCT;

ANALOGS AND DERIVATIVES; BRIEF PSYCHIATRIC RATING SCALE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG TOLERANCE; GINKGO BILOBA; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; EICOSAPENTAENOIC ACID; GINKGO BILOBA; HUMANS; PLANT PREPARATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84929142548     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0034-1385930     Document Type: Review

References (40)

1. Porcelli S., Balzarro B., Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol: 2012; 22 165 182
2. Lieberman J. A., Safferman A. Z., Pollack S. et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry: 1994; 151 1744 1752
3. Wolff-Menzler C., Hasan A., Malchow B. et al. Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry: 2010; 43 122 129
4. Sommer I. E., Begemann MJ H., Temmerman A. et al. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull: 2012; 38 1003 1011
5. Wang J., Omori I. M., Fenton M. et al. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev: 2010; CD008125
6. Taylor D. M., Smith L. Augmentation of clozapine with a second anti- psychotic - a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatrica Scandinavica: 2009; 119 419 425
7. Cipriani A., Boso M., Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev.: 2009; CD006324
8. Kontaxakis V. P., Ferentinos P. P., Havaki-Kontaxaki B. J. et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry: 2005; 20 409 415
9. Hedges L. V. Distribution theory for Glass's estimator of effect size and related estimators. J Educ Stat: 1981; 6 107 128
10. Freudenreich O., Henderson D. C., Walsh J. P. et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res: 2007; 92 90 94
11. Shadish W. R., Haddock C. K. Combining estimates of effect size. In Cooper H., Hedges L. V. eds. The Handbook of Research Synthesis. New York, NY Russell Sage Foundation: 1994; 261 281
12. Kelley G. A., Kelly K. S. Statistical models for meta-analysis: a brief tutorial. World J Methodol: 2012; 26 27 32
13. Higgins JP T., Thompson S. G., Deeks J. J. et al. Measuring inconsistency in meta-analyses. BMJ: 2003; 327 557 560
14. Rosenthal R. The 'file drawer problem' and tolerance for null effects. Psychol Bull: 1979; 86 638 641
15. Borenstein M., Hedges L., Higgins J. et al. Comprehensive Meta Analysis Version 2. Engelwood, NJ Biostat Inc: 2005
16. Gunduz-Bruce H., Oliver S., Gueorguieva R. et al. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophr. Res.: 2013; 143 344 347
17. Fleischhacker W. W., Heikkinen M. E., Olié J-P et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol: 2010; 13 1115 1125
18. Peet M., Horrobin D. F. (E-E Multicentre Study Group) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res: 2002; 36 7 18
19. Weiner E., Conley R. R., Ball M. P. et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology: 2010; 35 2274 2283
20. Mossaheb N., Sacher J., Wiesegger G. et al. Haloperidol in combination with clozapine in treatment-refractory patients with schizophrenia. Eur Neuropsychopharmacol: 2006; 16 416
21. Shiloh R., Zemishlany Z., Aizenberg D. et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry: 1997; 171 569 573
22. Assion H. J., Reinbold H., Lemanski S. et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry: 2008; 41 24 28
23. Nielsen J., Emborg C., Gydesen S. et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol: 2012; 32 173 178
24. Chang J. S., Ahn Y. M., Park H. J. et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-Controlled Trial. J Clin Psychiatry: 2008; 69 720 731
25. Muscatello M. R., Bruno A., Pandolfo G. et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res.: 2011; 127 93 99
26. Josiassen R. C., Joseph A., Kohegyi E. et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry: 2005; 162 130 136
27. Anil Yagcioglu A. E., Kiviricik Akdede B. B., Turgut T. I. et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry: 2005; 66 63 72
28. Honer W. G., Thornton A. E., Chen E. Y. et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med: 2006; 354 472 482
29. Buchanan R. W., Kirkpatrick B., Bryant N. et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry: 1996; 153 1625 1627
30. Zoccali R., Muscatello M. R., Cedro C. et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol: 2004; 19 71 76
31. Berk M., Gama C. S., Sundram S. et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol: 2009; 24 233 238
32. Lan G. X., Li Z. C., Li L. A randomized, placebo-controlled clinical trial of combined citalopram and clozapine in the treatment of negative symptoms of schizophrenia. Chin Mental Health J: 2006; 20 696 698
33. Mico U., Bruno A., Pandolfo G. et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int Clin Psychopharmacol: 2011; 26 303 310
34. Emsley R., Myburgh C., Oosthuizen P. et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry: 2002; 159 1596 1598
35. Small J. G., Klapper M. H., Malloy F. W. et al. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol: 2003; 23 223 228
36. Doruk A., Uzun O., Özşahin A. A placebo-controlled study of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol: 2008; 23 223 227
37. Newcomer J. W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs: 2005; 19 1 93
38. Brixner D. I., Said Q., Corey-Lisle P. K. et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother: 2006; 40 626 632
39. Englisch S., Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry: 2008; 32 1386 1392
40. Fan X., Borba C. P., Copeland P. et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand: 2013; 127 217 226